Wall Street analysts predict that Tokai Pharmaceuticals, Inc. (NASDAQ:NVUS) will report earnings per share of ($2.70) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Tokai Pharmaceuticals’ earnings. Tokai Pharmaceuticals posted earnings per share of ($4.59) in the same quarter last year, which would suggest a positive year-over-year growth rate of 41.2%. The firm is scheduled to report its next earnings report on Tuesday, June 20th.

According to Zacks, analysts expect that Tokai Pharmaceuticals will report full year earnings of ($6.98) per share for the current financial year, with EPS estimates ranging from ($10.00) to ($3.96). For the next financial year, analysts expect that the company will post earnings of ($3.51) per share. Zacks’ EPS calculations are an average based on a survey of research analysts that follow Tokai Pharmaceuticals.

Separately, Zacks Investment Research lowered Tokai Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 22nd. One research analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $1.08.

In other Tokai Pharmaceuticals news, insider Catherine C. Turkel bought 11,111 shares of the company’s stock in a transaction dated Wednesday, May 10th. The shares were purchased at an average cost of $9.99 per share, for a total transaction of $110,998.89. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Gregory J. Flesher acquired 58,959 shares of the stock in a transaction that occurred on Wednesday, May 10th. The stock was purchased at an average price of $9.99 per share, for a total transaction of $589,000.41. The disclosure for this purchase can be found here. 39.90% of the stock is owned by company insiders.

Shares of Tokai Pharmaceuticals (NASDAQ NVUS) opened at 5.50 on Monday. The company has a 50 day moving average price of $5.40 and a 200 day moving average price of $7.42. Tokai Pharmaceuticals has a one year low of $4.52 and a one year high of $61.04.

ILLEGAL ACTIVITY NOTICE: “Tokai Pharmaceuticals, Inc. (NVUS) Expected to Announce Earnings of -$2.70 Per Share” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/06/19/tokai-pharmaceuticals-inc-nvus-expected-to-announce-earnings-of-2-70-per-share.html.

Tokai Pharmaceuticals Company Profile

Novus Therapeutics, Inc, formerly Tokai Pharmaceuticals, Inc, is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities.

Get a free copy of the Zacks research report on Tokai Pharmaceuticals (NVUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.